Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Assunto principal
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mol Ther Nucleic Acids ; 34: 102066, 2023 Dec 12.
Artigo em Inglês | MEDLINE | ID: mdl-38034032

RESUMO

The European Cooperation in Science and Technology (COST) is an intergovernmental organization dedicated to funding and coordinating scientific and technological research in Europe, fostering collaboration among researchers and institutions across countries. Recently, COST Action funded the "Genome Editing to treat Human Diseases" (GenE-HumDi) network, uniting various stakeholders such as pharmaceutical companies, academic institutions, regulatory agencies, biotech firms, and patient advocacy groups. GenE-HumDi's primary objective is to expedite the application of genome editing for therapeutic purposes in treating human diseases. To achieve this goal, GenE-HumDi is organized in several working groups, each focusing on specific aspects. These groups aim to enhance genome editing technologies, assess delivery systems, address safety concerns, promote clinical translation, and develop regulatory guidelines. The network seeks to establish standard procedures and guidelines for these areas to standardize scientific practices and facilitate knowledge sharing. Furthermore, GenE-HumDi aims to communicate its findings to the public in accessible yet rigorous language, emphasizing genome editing's potential to revolutionize the treatment of many human diseases. The inaugural GenE-HumDi meeting, held in Granada, Spain, in March 2023, featured presentations from experts in the field, discussing recent breakthroughs in delivery methods, safety measures, clinical translation, and regulatory aspects related to gene editing.

2.
Ig Sanita Pubbl ; 65(1): 81-7, 2009.
Artigo em Italiano | MEDLINE | ID: mdl-19494925

RESUMO

Measles elimination is an important target for Public Health. Data on measles epidemiology in Italy are presented for years 2005-2008, after National Measles Elimination Plan was launched in 2003. In 2005 less than 300 case were notified but since 2006 outbreaks were detected in many Italian Regions. Even if vaccine coverage improved in last year, it did not reach the value necessary for elimination and there is the need to improve vaccination coverage and to implement effective infection control practices.


Assuntos
Sarampo/epidemiologia , Sarampo/prevenção & controle , Humanos , Itália/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA